Mary Caffrey

The study found that teenagers at the upper end of the "normal" BMI range later experienced higher death rates from lesser-known cardiovascular diseases.

Senate Majority Leader Mitch McConnell (R-Kentucky) faces the challenge of bridging the gap between conservatives who want a full Obamacare repeal and Republican members facing protests at home over losing Medicaid expansion.

Researchers who study diabetes camps have increasingly turned to the psychosocial benefits for children who gain opportunities to be around others like themselves.

The agreement will record data for patient experience, clinical improvement, and cost of care for patients switching from multiple daily injections to insulin pump therapy.

Legislation would give New Jersey's top insurance regulator new powers over Horizon's surplus, which the Blue Cross Blue Shield Association said would cause it to terminate Horizon's license. The bill also restores "insurer of last resort" status, which was abandoned in 1992.

The gap in disease incidence among ethnic groups demands a policy response, say experts who weighed in on the SEARCH data.

A different way to measure population aging takes into account changing life expectancy, with implications for healthcare.

The review of 8 studies on gastrointestinal injury related to exercise found that distress set in after the 2-hour mark, which is significant because no one has ever completed the 26.2-mile marathon in that time.

The study highlights the importance of Medicare's plan to launch the Diabetes Prevention Program in early 2018.

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

Liraglutide, a GLP-1 receptor agonist sold as Victoza, becomes the second diabetes therapy to receive the cardiovascular indication.

The Duke Center for Health Data Science was in the planning stages before Robert Califf, MD, departed for a stint as FDA commissioner.

The new law includes requirements that drugmakers reveal discounts for pharmacy benefit managers and prevents gag rules on pharmacists who want to suggest cheaper alternatives.

Experts hoped that Medicaid expansion would direct the previously uninsured into primary care and reduce reliance on the emergency department. What happened is more complicated.

Staff at mental health hospitals have long believed that tobacco helped calm patients, when in fact the nicotine only covered symptoms of withdrawal.

Cardiovascular outcomes trials and a photography ban that dominated social media were big news at the 77th Scientific Sessions of the American Diabetes Association.

The researchers' approach to finding the compound could be used to find cures in other diseases.

State-level decisions on whether to expand Medicaid had ripple effects across the rest of the healthcare insurance market, according to a report by the Office of the CMS Actuary in Health Affairs.

The collaboration between a digital behavioral health provider and an insurer comes as CMS admits challenges setting up the Medicare Diabetes Prevention Program.

Studies presented at the 77th Scientific Sessions of the American Diabetes Association show that the combination therapy helps patients with the highest glycated hemoglobin levels gain control quickly.

The study's lead author said that complications from cardiovascular disease remain an unmet clinical challenge in type 2 diabetes.

A light-hearted format for the discussion at the 77th Scientific Sessions of the American Diabetes Association still brought out the seriousness of the issue: too many with type 2 diabetes have poor glycemic control, and another medication may not be the answer.

The long-awaited results from CANVAS show a reduced risk of cardiovascular events. The study's lead author said clinicians should balance the significant benefits of the drug against the potential harms for a small number of patients with known risks.

Results presented at the 77th Scientific Sessions of the American Diabetes Association are for combinations with ertugliflozin, an investigational SGLT2 inhibitor before FDA.

At a symposium at the 77th Scientific Sessions of the American Diabetes Association, experts suggested that the relationship between heart failure and diabetes is finally getting the attention it deserves.

The studies are the first to focus on use of PCSK9 inhibitors in patients with diabetes. Alirocumab, sold as Praluent, is expected to report its cardiovascular outcomes trial in early 2018.

No one questions the long-term savings that the Diabetes Prevention Program will bring to Medicare, but getting it off the ground will require several steps that have never been done before, including a new payment model.

With the nation's largest commercial payer on board, the maker of the at-home DNA colon cancer screening test will put more focus on physician education and consumer awareness, with the hope of increasing screening rates for a test that patients find uncomfortable and inconvenient.

The investigational oral therapy, upadacitinib, is a potential competitor for Pfizer's JAK inhibitor, which treats patients who are not responding adequately to DMARDs.